Retina Implant gains approval for extended European clinical trials

Article

Retina Implant's scientific advisory board has approved the expansion of the European clinical trials for its subretinal implants for retinitis pigmentosa patients.

Retina Implant's scientific advisory board has approved the expansion of the European clinical trials for its subretinal implants for retinitis pigmentosa patients.

The trial commenced in Tübingen, Gemany in 2010. The multicentre phase of Retina Implant's second human clinical trial will take place in Germany, Budapest, London and Oxford. The study involves patients keeping the implant in permanently so it can be used in everyday situations.

Nine patients were implanted with Retina Implant's wireless device between May 2010 and July 2011. The findings saw patients presenting with the best visual acuity recorded so far. The majority of patients experienced restored vision for everyday life. Visual perception in dim and bright environments was achieved in a significant number of patients.

Professor MacLaren, professor of ophthalmology at Oxford University Hospitals NHS Trust, said, "We are delighted to be involved in testing this pioneering subretinal implant technology. The results achieved by the Retina Implant team to-date represent a significant advance in this technology that could greatly enhance the quality of life for people with an incurable, blinding disease."

Dr Walter G. Wrobel, CEO of Retina Implant, said, "We are pleased that after reviewing the results of the first nine patients in the trial, the scientific advisory board is in agreement that the next stage of our research should begin. The Board's continued support reinforces the progress Retina Implant continues to make on our journey to permanently restore useful vision to retinitis pigmentosa patients."

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.